Form 4 for GNLX GENELUX Corp
Accepted 2023-09-18 00:00:00 ET · period of report 2023-09-15 · accession 0001209191-23-049841 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-18 | 2023-09-15 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +10.4K | 116.5K | +10% | +$62.4K |
| DM | 2023-09-18 | 2023-09-15 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $21.89 | -10.4K | 110.8K | -9% | -$227.6K |
| D | 2023-09-18 | 2023-09-15 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $0.00 | -10.4K | 229.3K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-15 | M | A | 10,400 | $6.00 | 116,535 | D | — | — | |
| 2 | Common | Common Stock | 2023-09-15 | S | D | 4,675 | $22.29 | 106,135 | D | — | — | (F3) The weighted average sale price for the transaction reported was $22.2913, and the range of prices were between $22.02 and $22.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2023-09-15 | S | D | 5,725 | $21.56 | 110,810 | D | — | — | (F2) The weighted average sale price for the transaction reported was $21.5578, and the range of prices were between $21.01 and $21.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 4 | Derivative | Stock Option (right to buy) | 2023-09-15 | M | D | 10,400 | $0.00 | 229,253 | D | $6.00 · — to 2029-09-20 | 10,400 Common Stock | (F4) Immediately exercisable. |